Table 3.
PSA and radiological response of all patients as grouped by bone scan response
| Pt. | PSA baseline (ng/ml) | PSA F/U* (ng/ml) | PSA change (%) | Bone scan* | CT scan* |
|---|---|---|---|---|---|
| 1 | 25 | 16.3 | -35% | CR | PR (retroperitoneal nodes) |
| 2 | 460.8 | 1620 | 252% | PR | PD (New liver metastasis) |
| 3 | 311.1 | 966 | 211% | PR | PD (New liver metastasis) |
| 4 | 110.7 | 132.8 | 20% | PR | |
| 5 | 110.6 | 115 | 4% | PR | |
| 6 | 598.9 | 592.4 | -1% | PR | PR (pelvic side wall mass and nodes) |
| 7 | 41.9 | 117.6 | 180% | SD | SD (pulmonary metastasis) |
| 8 | 33.5 | 90.9 | 171% | SD | PD (New nodal metastasis) |
| 9 | 212.3 | 555.2 | 162% | SD | |
| 10 | 21.2 | 32.9 | 55% | SD | |
| 11 | 7.6 | 11 | 45% | SD | |
| 12 | 21 | 23 | 10% | SD | |
| 13 | 26 | 17.5 | -33% | SD | |
| 14 | 6.3 | 2.9 | -54% | SD | |
| 15 | 17.6 | 6.31 | -64% | SD | PR (retroperitoneal nodes) |
| 16 | 29.8 | 135 | 353% | PD | PD (retroperitoneal nodes) |
| 17 | 40.8 | 162.8 | 299% | PD | |
| 18 | 388.1 | 1412 | 264% | PD | |
| 19 | 47 | 66.9 | 42% | PD | |
| 20 | 135 | 162 | 20% | PD | |
| 21 | 34.1 | 27.5 | -20% | PD | |
| 22 | 14.6 | 8.8 | -40% | PD | |
| 23 | 157 | 557.9 | 255% | NE | |
| 24 | 28.4 | 77.1 | 172% | NE | |
| 25 | 283.9 | 251.4 | -11% | NE | |
| 26 | 28.2 | 75.6 | 168% | No progressionϕ | |
| 27 | 7 | 7.22 | 3% | No progressionϕ | |
| 28 | 31.6 | 26.7 | -16% | No progressionϕ | SD (pelvic nodes) |
Abbreviations: Pt, patient; PSA, prostate-specific antigen; F/U, follow up
*
Evaluate 12 weeks after treatment
ϕ
Bone scan did not show metastasis at baseline and during follow up